GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » Total Assets

GenMark Diagnostics (GenMark Diagnostics) Total Assets : $223.5 Mil (As of Dec. 2020)


View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics Total Assets?

GenMark Diagnostics's Total Assets for the quarter that ended in Dec. 2020 was $223.5 Mil.

Warning Sign:

If a company builds asset at 25% a year, faster than its revenue growth rate of 19.2% over the past 5 years, it means that the company may be getting less efficent.

During the past 12 months, GenMark Diagnostics's average Total Assets Growth Rate was 64.40% per year. During the past 3 years, the average Total Assets Growth Rate was 23.80% per year. During the past 5 years, the average Total Assets Growth Rate was 25.00% per year. During the past 10 years, the average Total Assets Growth Rate was 28.20% per year.

During the past 13 years, GenMark Diagnostics's highest 3-Year average Total Assets Growth Rate was 80.50%. The lowest was 7.40%. And the median was 28.30%.

Total Assets is connected with ROA %. GenMark Diagnostics's annualized ROA % for the quarter that ended in Dec. 2020 was -6.80%. Total Assets is also linked to Revenue through Asset Turnover. GenMark Diagnostics's Asset Turnover for the quarter that ended in Dec. 2020 was 0.23.


GenMark Diagnostics Total Assets Historical Data

The historical data trend for GenMark Diagnostics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GenMark Diagnostics Total Assets Chart

GenMark Diagnostics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.32 122.30 92.98 111.47 223.53

GenMark Diagnostics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.47 111.59 195.01 214.59 223.53

GenMark Diagnostics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

GenMark Diagnostics's Total Assets for the fiscal year that ended in Dec. 2020 is calculated as

Total Assets=Total Equity (A: Dec. 2020 )+Total Liabilities (A: Dec. 2020 )
=94.198+129.336
=223.5

GenMark Diagnostics's Total Assets for the quarter that ended in Dec. 2020 is calculated as

Total Assets=Total Equity (Q: Dec. 2020 )+Total Liabilities (Q: Dec. 2020 )
=94.198+129.336
=223.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GenMark Diagnostics  (NAS:GNMK) Total Assets Explanation

Total Assets is connected with ROA %.

GenMark Diagnostics's annualized ROA % for the quarter that ended in Dec. 2020 is

ROA %=Net Income (Q: Dec. 2020 )/( (Total Assets (Q: Sep. 2020 )+Total Assets (Q: Dec. 2020 ))/ count )
=-14.896/( (214.59+223.534)/ 2 )
=-14.896/219.062
=-6.80 %

Note: The Net Income data used here is four times the quarterly (Dec. 2020) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

GenMark Diagnostics's Asset Turnover for the quarter that ended in Dec. 2020 is

Asset Turnover
=Revenue (Q: Dec. 2020 )/( (Total Assets (Q: Sep. 2020 )+Total Assets (Q: Dec. 2020 ))/ count )
=50.08/( (214.59+223.534)/ 2 )
=50.08/219.062
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

GenMark Diagnostics Total Assets Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


GenMark Diagnostics (GenMark Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
5964 La Place Court, Carlsbad, CA, USA, 92008-8829
GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.
Executives
Tyler Jensen officer: SVP, Engineering and Tech Dev 5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw officer: VP, Assay Development 5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo officer: VP, Qual, Reg, & Clin Affairs 5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson officer: SVP, Corp. Accounts 5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler officer: VP, Human Resources 5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins officer: SVP, Sales 5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director, officer: President & CEO 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier officer: SVP & General Counsel 5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell officer: SVP, Operations 5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner director 5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff director DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox director 5964 LA PLACE COURT, CARLSBAD CA 92008

GenMark Diagnostics (GenMark Diagnostics) Headlines

From GuruFocus

Genmark Diagnostics Inc (GNMK) President & CEO Scott Mendel Sold $751,000 of Shares

By GuruFocus Research GuruFocus Editor 08-28-2020